Results 21 to 30 of about 281,370 (287)

Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody) [PDF]

International Journal of Molecular Sciences, 2020
Antibody drug conjugates (ADCs), consisting of a cancer-specific antibody and cytotoxic payload, are shown to be a potent class of anticancer therapeutics, with enhanced therapeutic efficacy and reduced “off-target” side effects. However, the therapeutic window of ADCs is narrowed by problems such as difficulty in site-specific conjugation of payload ...
Hyun Jung Kim, Ho Jin Sung, Yul Min Lee, Sun Il Choi, Yun-Hee Kim, Kyun Heo, In-Hoo Kim   +6 more
openaire   +2 more sources

Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers

European Journal of Breast Health, 2019
Objective:Breast cancer is the most common cancer among women worldwide. Adenine thymine-rich interactive domain 1A (ARIDIA) is a tumor suppressor gene involved in chromatin remodeling and it encodes the ARIDIA protein. Recent studies have shown the loss
Melek Ünçel, Gülden Diniz, Gamze Aköz, Zübeyde Yıldırım Ekin, Sevil Sayhan, Serdar Yardım, Semra Salimoğlu   +6 more
doaj   +1 more source

Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines

South Asian Journal of Cancer, 2022
Biren Parikh Introduction Hormonal status and HER2 expression are valuable biomarkers and dictate the management of the patients diagnosed with invasive breast cancer (IBC).
B. R. Nagarjun, Biren Parikh, Manaswi Nareshkumar Patel, Pina J. Trivedi, Dharmesh M. Patel   +4 more
doaj   +1 more source

First-line therapy in HER2 positive metastatic breast cancer. Is the mosaic fully completed or are we missing additional pieces? [PDF]

, 2016
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advanced ...
Cognetti F., Fabi A., Malaguti P., Vari S.   +3 more
core   +2 more sources

HER2 testing in breast cancer: Opportunities and challenges [PDF]

, 2006
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-25% of breast cancers, usually as a result of HER2 gene amplification. Positive HER2 status is considered to be an adverse prognostic factor. Recognition of the role of HER2 in breast
Annette Lebeau, Arnould L, Baselga J, Bast, Bilous M, Carter P, Cho HS, Clynes RA, Cobleigh MA, Connor CS, Crowder RJ, Dandachi N, De Laurentiis M, Di Leo A, Di Loreto C, Goldhirsch A, Gschwind A, Hancock MC, Hanna W, Harari D, Hortobagyi GN, Hudziak RM, Jacobs TW, Kobayashi M, Lebeau A, Lohrisch C, Mass R, Mass R, Molina MA, Mueller-Holzner E, Nagata Y, Osborne CK, Paik S, Piccart MJ, Piccart-Gebhart MJ, Pietras RJ, Pinto AE, Revillion F, Romond EP, Ross JS, Seidman AD, Sliwkowski MX, Tanner M, Taucher S, Yakes FM, Yarden Y   +45 more
core   +1 more source

HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer [PDF]

American Journal of Clinical Pathology, 2017
Approximately 15% of breast cancers show equivocal human epidermal growth factor receptor 2 (HER2) results on HER2 immunohistochemistry (IHC) and are reflexed for fluorescence in situ hybridization (FISH). However, some cases remain equivocal. In this study, we evaluated these double-equivocal cases by using a novel gene protein assay (GPA), which can ...
Yanjun, Hou, Hiroaki, Nitta, Zaibo, Li
openaire   +2 more sources

Improving HER2 testing reproducibility in HER2-low breast cancer

Cancer Drug Resistance, 2022
HER2 is a pillar biomarker in breast cancer, and it is assessed by immunohistochemistry (IHC) using a three-tier scoring system and reflex in situ hybridization (ISH) for IHC score 2+. Novel HER2-directed antibody-drug conjugates have demonstrated significant antitumor activity in breast cancers with low levels of HER2 expression, i.e.
Sajjadi E., Venetis K., Ivanova M., Fusco N.   +3 more
openaire   +2 more sources

[18F]FDG PET/CT volumetric biomarkers for non-invasive prediction of HER2 expression in breast cancer patients [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology
Objective(s): to investigate the capability of 18F-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]-FDG PET/CT) derived volumetric parameters to predict human epidermal growth factor receptor 2 (HER2) status in breast cancer ...
Mai ELahmadawy, Heba Abdelhameed, Dina Gamal El-din, Mahitab Eltohamy, Adel Hassan, Salwa Abd El-Gaid   +5 more
doaj   +1 more source

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. [PDF]

, 2017
Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature.
Berry, Don, Brown-Swigart, Lamorna, Buxton, Meredith, DeMichele, Angela, Esserman, Laura, Glas, Annuska, Hirst, Gillian, Hylton, Nola, Linn, Sabine, Olopade, Olufunmilayo, Paoloni, Melissa, Petricoin, Emanuel, Rugo, Hope, Sanil, Ashish, Severson, Tesa M, Symmans, Fraser, van 't Veer, Laura, Wolf, Denise M, Wulfkuhle, Julia, Yau, Christina, Yee, Doug   +20 more
core   +2 more sources

Insulin receptor substrate 4 (IRS4) is a constitutive active oncogenic driver collaborating with HER2 and causing therapeutic resistance

Molecular & Cellular Oncology, 2017
Insulin receptor substrate 4 (IRS4) belongs to a family of cytoplasmic docking proteins mediating signals from cell surface receptors to downstream effectors.
Gerjon J. Ikink, John Hilkens
doaj   +1 more source